In inflammatory breast cancer (IBC) models, PARP1 inhibitors achieve radiosensitization by delaying DNA double-strand break repair, an effect partially dependent on BRCA1 mutation status (44). This evidence concerns the gene PARP1 and inflammatory breast carcinoma.